<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040634</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMAL-DIABETES Trial</org_study_id>
    <secondary_id>02795218.8.1001.0071</secondary_id>
    <secondary_id>25000.028978/2018-02</secondary_id>
    <nct_id>NCT04040634</nct_id>
  </id_info>
  <brief_title>Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)</brief_title>
  <official_title>Large-Scale Randomized Clinical Trial Assessing Intensive Blood Pressure Control for Reduction of Major Cardiovascular Events in Patients With Diabetes Mellitus (OPTIMAL-DIABETES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood pressure (BP) is a major public health concern, especially in low and middle
      income countries. High BP is a highly prevalent condition, and it is usually associated with
      diabetes mellitus. Both high BP and diabetes are risk factors for major cardiovascular events
      including cardiovascular death, acute myocardial infarction, stroke, unstable angina and
      heart failure. In addition, high BP is also related to cognitive decline. The
      OPTIMAL-DIABETES trial consists of a two-arm, multicenter, randomized clinical trial designed
      to test whether a lower systolic blood pressure (SBP) target will reduce the occurrence of
      major cardiovascular events in diabetic patients compared to the standard SBP target.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to first event of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to first event of cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to total death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to first event of total death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to all cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cardiovascular Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to death from cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Renal Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to death from renal causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Myocardial Infarction (MI)</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to myocardial infarction (MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ischemic Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hemorrhagic Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Undetermined type of Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Undetermined type of Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Transient Ischemic Attack (TIA)</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to transient ischemic attack (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospitalization for Unstable Angina</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Hospitalization for unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospitalization for Heart Failure</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Renal Outcome</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Renal Outcome, defined as a 50% reduction in the glomerular filtration rate (GRF) associated with a final GFR of &lt; 60 mL/min/1.73m2 in patients without chronic kidney disease (GFR 60-90 mL/min/1.73m2) at baseline. In those patients with chronic kidney disease (&lt;60 mL/min/1.73m2) at baseline, the renal outcome will be defined as a 50% reduction in GFR or progression of renal disease to stage IV, requiring dialysis or kidney transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mild Cognitive Impairment</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Mild Cognitive Impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mild Cognitive Impairment or All-Cause Probable Dementia</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to mild cognitive impairment or all-cause probable dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to All-Cause Probable Dementia</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to all-cause probable dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Brain Volume</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Total Brain Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Matter Lesions Volume</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>White Matter Lesions Volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9000</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>High Blood Pressure</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Intensive Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP &lt;120 mm Hg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized into the Standard arm will have a goal of SBP &lt;140 mm Hg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Control of Systolic Blood Pressure (SBP)</intervention_name>
    <description>Participants in the Intensive arm have a goal of SBP &lt;120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged.</description>
    <arm_group_label>Intensive Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <other_name>Intensive BP control targeting SBP &lt;120 mm Hg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard control of Systolic Blood Pressure (SBP)</intervention_name>
    <description>The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
    <arm_group_label>Standard Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <other_name>Standard control of SBP targeting SBP &lt; 140 mm Hg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systolic Blood Pressure (SBP) between 130 and 180 mm Hg:

               -  130 to 150 mm Hg (if on 0-4 medications)

               -  130 to 160 mm Hg (if on 0-3 medications)

               -  130 to 170 mm Hg (if on 0-2 medications)

               -  130 to 180 mm Hg (if on 0-1 medications)

          -  Type 2 diabetes

          -  To be considered as having a high cardiovascular risk, including AT LEAST ONE of the
             following factors:

               1. Established cardiovascular disease (CVD), including:

                    -  Coronary artery disease: previous myocardial infarction, previous acute
                       coronary syndrome, previous percutaneous coronary intervention, previous
                       coronary artery bypass graft surgery, or at least 50% stenosis in a main
                       coronary artery associated with typical angina pectoris; or

                    -  Cerebrovascular disease: previous stroke (except those events caused by
                       intracranial aneurysm or arteriovenous malformation) or previous transient
                       ischemic attack (TIA), stable for at least 2 weeks preceding inclusion in
                       the study; or

                    -  Carotid artery disease: previous carotid endarterectomy, previous
                       percutaneous intervention with carotid stent implantation, or asymptomatic
                       stenosis of at least 50% in a carotid shown by the Doppler ultrasonography;
                       or

                    -  Peripheral artery disease: prior surgical or percutaneous revascularization
                       of a peripheral artery, limb amputation due to vascular cause, abdominal
                       aortic aneurysm ≥ 5 cm (with or without prior surgical or percutaneous
                       repair), or stenosis of at least 50% in a peripheral artery associated to
                       intermittent claudication.

               2. Subclinical CVD, including:

                    -  Coronary calcium score ≥ 300 Agatston units; or

                    -  Ankle-brachial index ≤ 0.90 in the last two years; or

                    -  Left ventricular hypertrophy on the electrocardiogram, echocardiogram or
                       other cardiac imaging exam in the last two years.

               3. Chronic kidney disease (CKD):

                  ▪ Definition of CKD: glomerular filtration rate (GFR) between 20 and 59
                  ml/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration
                  (CKD-EPI).

               4. Additional cardiovascular risk factors, including:

                    -  Active smoking: Defined as regular use of cigarettes or other tobacco
                       products, such as cigars and pipe, in the last six months;

                    -  Dyslipidemia: Defined as LDL cholesterol &gt; 70 mg/dL or non-HDL cholesterol &gt;
                       100 mg/dL in patients with previous CVD; or LDL cholesterol &gt; 100 mg/dL or
                       non-HDL cholesterol &gt; 130 mg/dL in patients without previous CVD; or
                       Triglycerides &gt; 200 mg/dL or HDL &lt; 40 mg/dL regardless of treatment; or use
                       of statins or other lipid lowering medication; or

                    -  Age ≥ 75 years

        Exclusion Criteria:

          -  Refusal to provide written informed consent

          -  Body mass index &gt; 45 kg/m2

          -  Known secondary cause of hypertension

          -  Severe renal dysfunction with GFR &lt; 20 mL/min/1.73m2 calculated by the CKD-EPI
             equation

          -  Angina at rest Class IV Canadian Cardiovascular Society (CCS)

          -  Acute coronary syndrome in the last six months

          -  Symptomatic heart failure Class IV New York Heart Association (NYHA) or ejection
             fraction &lt; 35% on Doppler echocardiography in the last six months

          -  Factors that at the research team´s judgment may limit adherence to the intervention
             and study protocol, including, but not limited to, the following examples:

               -  Recent history of alcohol and illicit drug abuse

               -  Psychiatric comorbidities (severe depression, schizophrenia, psychosis, etc.)

               -  History of poor medication adherence and attendance to consultations

               -  Any plans to move the city of residence in the next four years

               -  Any plans to leave the city of residence for more than three months in the next
                  few years

               -  Living in the same residence of another patient previously included in this study

          -  Patients currently enrolled in another study for CVD prevention, including those
             evaluating pharmacological and non-pharmacological interventions

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otavio Berwanger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karla Santo, MD, PhD</last_name>
    <phone>+55 11 2151-5915</phone>
    <email>karla.santo@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diogo Moia</last_name>
    <phone>+55 11 2151-5915</phone>
    <email>diogo.moia@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Pesquisas Clínicas Dr Marco Mota</name>
      <address>
        <city>Maceió</city>
        <state>Alagoas</state>
        <zip>57051-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelise Paiva</last_name>
      <phone>+558232155032</phone>
    </contact>
    <investigator>
      <last_name>Marco Antonio Mota Gomes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas em Diabetes e Doenças Endocrino-Metabólicas</name>
      <address>
        <city>Fortaleza</city>
        <state>Bahia</state>
        <zip>60430-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Hissa</last_name>
      <phone>+558532146530</phone>
    </contact>
    <investigator>
      <last_name>Miguel N Hissa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ana Nery</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40323-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Dorta</last_name>
      <phone>+557131171800</phone>
    </contact>
    <investigator>
      <last_name>Luiz Carlos Passos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Hospital de Base</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>70330-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thais Coutinho</last_name>
      <phone>+556133151345</phone>
    </contact>
    <investigator>
      <last_name>Ana Claudia Nogueira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Cassiano Antonio de Moraes</name>
      <address>
        <city>Vitória</city>
        <state>Espirito Santo</state>
        <zip>29043-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thais Ruchdeschel</last_name>
      <phone>+552733352918</phone>
    </contact>
    <investigator>
      <last_name>José Geraldo Mill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Goiás</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Luiza Souza</last_name>
      <phone>+556232698551</phone>
    </contact>
    <investigator>
      <last_name>Weimar Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NS Clínica de Diabetes e Endocrinologia Ltda</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Costa</last_name>
      <phone>+556230967400</phone>
    </contact>
    <investigator>
      <last_name>Nelson Rassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Correa</last_name>
      <phone>+553132259559</phone>
    </contact>
    <investigator>
      <last_name>Antonio LP Ribeiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa do Hospital Santa Lúcia</name>
      <address>
        <city>Poços De Caldas</city>
        <state>Minas Gerais</state>
        <zip>37710-005</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gislayne Ribeiro</last_name>
      <phone>+553537224463</phone>
    </contact>
    <investigator>
      <last_name>Ricardo Bergo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pronto Socorro Cardiológico de Pernambuco Prof. Luiz Tavares da Silva</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50100-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Dorta</last_name>
      <phone>+558130353045</phone>
    </contact>
    <investigator>
      <last_name>Audes Feitosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pronto Socorro Cardiológico de Pernambuco Prof. Luiz Tavares da Silva</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50100-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cleide Freire</last_name>
      <phone>+558131817133</phone>
    </contact>
    <investigator>
      <last_name>Dario Sobral Filho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosane Schlatter</last_name>
      <phone>+555133597872</phone>
    </contact>
    <investigator>
      <last_name>Sandra Fuchs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Mira</last_name>
      <phone>+555133205120</phone>
    </contact>
    <investigator>
      <last_name>Mario Wiehe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Coração</name>
      <address>
        <city>Aracaju</city>
        <state>Sergipe</state>
        <zip>49055-530</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maelyn Silveira</last_name>
      <phone>+557930259700</phone>
    </contact>
    <investigator>
      <last_name>Fábio Serra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Endocrinologia Geloneze</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Coghi</last_name>
      <phone>+551932131443</phone>
    </contact>
    <investigator>
      <last_name>Bruno Geloneze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrique Carvalho</last_name>
      <phone>+551639636476</phone>
    </contact>
    <investigator>
      <last_name>Maria Cristinas F Freitas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integrado de Pesquisas</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadielly Prado</last_name>
      <phone>+551732015054</phone>
    </contact>
    <investigator>
      <last_name>Lilia N Maia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Vilela &amp; Martin</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-365</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiane Azevedo</last_name>
      <phone>+551733537007</phone>
    </contact>
    <investigator>
      <last_name>José Fernando V Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia e Endocrinologia Rio Preto Ltda</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15091-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiane Rubio</last_name>
      <phone>+551732278195</phone>
    </contact>
    <investigator>
      <last_name>Juan Carlos Toledo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Cardiológica</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <zip>15505-189</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiane Azevedo</last_name>
      <phone>+551734224804</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth ES Cestario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Ciências Médicas - Universidade do Estado do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Offrede</last_name>
      <phone>+552126204093</phone>
    </contact>
    <investigator>
      <last_name>Andrea Brandão, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica de Metabologia e Hipertensão da Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04025-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Nakamichi</last_name>
      <phone>+551159040400</phone>
    </contact>
    <investigator>
      <last_name>Marcelo Batista, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Elisa</last_name>
      <phone>+551126617686</phone>
    </contact>
    <investigator>
      <last_name>Luciano Drager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Gonçalves</last_name>
      <phone>+551126615334</phone>
    </contact>
    <investigator>
      <last_name>Luiz Bortolotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

